Project Grant R01NS134986
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke awarded the University of Colorado-Denver a $198,129 K23 Career Development Grant (CFDA 93.279 – Drug Use and Addiction Research Programs) effective August 18, 2025, through July 31, 2030. This award supports a feasibility trial of a remotely-delivered mindfulness-based intervention (MBI) program adapted specifically for adolescents with migraine. The principal investigator will develop and preliminarily test...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded the University of Pittsburgh a $782,547 Project Grant on August 19, 2025, under the Mental Health Research Grants program (CFDA 93.242) to investigate the role of puberty in corticostriatal circuitry development and avoidance behavior in adolescents with anxiety disorders. The research will extend through July 31, 2030, and focuses on understanding how pubertal hormones impact reward processing and learning...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $415,249 to the Regents of the University of Michigan on August 7, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). This Project Grant supports a two-year research initiative (through July 31, 2027) to develop predictive measures for migraine attack onset through continuous monitoring of autonomic nervous system...
- Federal Project Grant Summary The National Institute on Aging (NIA) awarded a $317,000 Project Grant to Indiana University Indianapolis on September 1, 2025, under the Aging Research program (CFDA 93.866) to investigate chronic migraine as an early biomarker of Alzheimer's disease (AD). The research will deliver scientific knowledge regarding the mechanistic relationship between migraine disorders and AD pathology, addressing a significant gap in the field where elevated AD incidence in migraine...
- Federal Project Grant Award Summary The National Institute of Mental Health (NIMH) awarded the University of Pittsburgh a Project Grant totaling $190,188 under the Mental Health Research Grants program (CFDA 93.242), effective June 3, 2026, through May 31, 2031. This five-year research initiative investigates the neural substrates underlying perseverative thought disengagement and reward learning in early adolescent girls, with particular focus on the role of puberty in the development of...
- Federal Grant Award Summary The National Center for Complementary and Integrative Health (NCCIH) awarded Children's Mercy Hospital a $1.5M Project Grant (CFDA 93.213: Research and Training in Complementary and Integrative Health) on September 22, 2025, to conduct a pre-efficacy feasibility trial of Immersive Neurofeedback Self-Regulation Training (INSERT) for pediatric migraine prevention. The research will evaluate the practical implementation and clinical feasibility of a home-based...
- Federal Grant Award Summary The University of Virginia received a $444,125 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, effective July 18, 2025, with an ultimate completion date of June 30, 2027. The award funds research investigating the role of progesterone receptors in migraine chronification—specifically, the mechanisms by which...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded the University of Pittsburgh a $185,552 Project Grant effective September 19, 2025, under the Mental Health Research Grants program (CFDA 93.242) to investigate neurocognitive responses to social threat and their connection to suicidality in adolescent girls. The research will generate scientific knowledge through a K23 mentored research career development award examining how sustained neural responsivity to...
- Federal Project Grant Award Summary Seattle Children's Research Institute received a $1.52 million Project Grant from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865), awarded August 15, 2025, through April 30, 2030. The grant funds a longitudinal research study investigating the causal relationships between sleep deficiency and menstrual pain in adolescent females aged 13-16 years. The...
- This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $419,375.00 to support research on the role of the GPR37L1 receptor in chronic migraine. The funding will enable a research team at Florida Atlantic University, with a sub-award to the University of Florida, to conduct a comprehensive investigation into the involvement of GPR37L1 signaling in the neuropathology of...
MIGRAINE PROGNOSIS IN ADOLESCENTS - PROJECT SUMMARY MIGRAINE IS A HIGHLY PREVALENT AND DISABLING DISORDER THAT AFFECTS 15% OF CHILDREN AND ADOLESCENTS WORLDWIDE. ADOLESCENTS WITH MIGRAINE FREQUENTLY UNDERGO CHANGES IN THEIR DISEASE SYMPTOMS DURING PUBERTY, WITH INDIVIDUALS EXPERIENCING INCREASES, DECREASES, OR NO CHANGE IN HEADACHE FREQUENCY. IT IS NOT CURRENTLY POSSIBLE TO PREDICT IF AN INDIVIDUAL WILL EXPERIENCE IMPROVEMENT, NO CHANGE, OR WORSENING OF MIGRAINE SYMPTOMS, AND THE UNDERLYING MECHANISMS CONTROLLING THESE CHANGES REMAIN UNCHARACTERIZED. THUS, IN THE PROPOSED STUDY, WE AIM TO IDENTIFY THE BASELINE FACTORS DETERMINING MIGRAINE PROGNOSES IN ADOLESCENTS (AIM 1), DETERMINE THE HORMONAL, NEURAL, AND PSYCHOPHYSICAL CHANGES RELATED TO MIGRAINE PROGNOSES IN ADOLESCENTS (AIM 2A), AND IDENTIFY THE TEMPORAL RELATIONSHIPS BETWEEN HORMONAL, NEURAL, AND PSYCHOPHYSICAL CHANGES PRECEDING VS. FOLLOWING CHANGES IN HEADACHE FREQUENCY (AIM 2B). PRELIMINARY DATA SUPPORT TESTOSTERONE LEVELS, CONDITIONED PAIN MODULATION (CPM) RESPONSE, AND FUNCTIONAL CONNECTIVITY (FC) OF THE AMYGDALA AS FACTORS THAT MAY DETERMINE MIGRAINE PROGNOSIS. OUR PRELIMINARY DATA INDICATE THAT CPM RESPONSE AND AMYGDALAR FC AT BASELINE MAY PREDICT THE CHANGE IN HEADACHE FREQUENCY FOLLOWING A BEHAVIORAL INTERVENTION IN ADOLESCENTS WITH MIGRAINE. IN ADDITION, CHANGES IN TESTOSTERONE LEVELS ARE ASSOCIATED WITH CHANGES IN MIGRAINE SYMPTOMS. STUDY PARTICIPANTS WILL BE ADOLESCENTS WITH EPISODIC MIGRAINE (AGES 10-13, 50% FEMALES, MIGRAINE ONSET > 6 MONTHS, HEADACHE FREQUENCY BETWEEN 4-15/MONTH, WITHOUT OR WITH A STABLE PREVENTATIVE TREATMENT FOR MIGRAINE). PSYCHOPHYSICAL, NEURAL, AND HORMONAL FACTORS WILL BE ASSESSED AT BASELINE AND AT 1- AND 2-YEAR FOLLOW-UPS. PARTICIPANTS WILL MEET WITH A HEADACHE SPECIALIST AT ALL STUDY VISITS TO CONFIRM MIGRAINE DIAGNOSIS AND FOR RIGOROUS CHARACTERIZATION OF MIGRAINE SYMPTOMS. MIGRAINE OUTCOMES WILL BE CATEGORIZED AS AN INCREASE OR DECREASE (> 30%) OR NO CHANGE (< 30%) IN HEADACHE FREQUENCY FROM BASELINE TO 2-YEAR FOLLOW-UP. A HEALTHY CONTROL GROUP WILL COMPLETE ALL STUDY PROCEDURES TO CONTROL FOR NORMAL PUBERTAL CHANGES. WE HYPOTHESIZE THAT MALE SEX AND GREATER CPM RESPONSES, LOWER AMYGDALA-PREFRONTAL CORTEX (PFC) FC, AND HIGHER TESTOSTERONE LEVELS AT BASELINE WILL BE ASSOCIATED WITH A DECREASE IN HEADACHE FREQUENCY AFTER TWO YEARS. WE EXPECT THAT ADOLESCENTS WITH INCREASED HEADACHE FREQUENCY WILL HAVE A GREATER REDUCTION IN CPM EFFICIENCY, INCREASED AMYGDALA-PFC FC, AND A SMALLER INCREASE IN TESTOSTERONE LEVELS COMPARED TO ADOLESCENTS WITH A DECREASE OR NO CHANGE IN HEADACHE FREQUENCY AND HEALTHY ADOLESCENTS. WE EXPECT SMALLER INCREASES IN TESTOSTERONE LEVELS TO PRECEDE INCREASES IN HEADACHE FREQUENCY AND GREATER REDUCTIONS IN CPM EFFICIENCY AND INCREASES IN AMYGDALA-PFC FC TO FOLLOW INCREASES IN HEADACHE FREQUENCY. CHARACTERIZING THE MECHANISMS UNDERLYING CHANGES IN MIGRAINE SYMPTOMS IS IMPERATIVE FOR THE DEVELOPMENT OF NEW MIGRAINE TREATMENTS. IDENTIFICATION OF ADOLESCENTS WHO ARE AT RISK OF WORSENING MIGRAINE SYMPTOMS DURING PUBERTY WILL FACILITATE THE DEVELOPMENT OF PERSONALIZED EARLY-PREVENTIVE STRATEGIES, WHICH CAN REDUCE PATIENT BURDEN.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $615.4k | 7/1/25 | ||
| Not listed | $600.9k | 6/28/24 |